[HTML][HTML] Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties
CP Larsen, TC Pearson, AB Adams, P Tso… - American Journal of …, 2005 - Elsevier
Current success in organ transplantation is dependent upon the use of calcineurin-inhibitor-
based im-munosuppressive regimens. Unfortunately, current immunotherapy targets
molecules with ubiquitous ex-pression resulting in devastating non-immune side effects. T-
cell costimulation has been identified as a new potential immunosuppressive target. The
best characterized pathway includes CD28, its homologue CTLA4 and their ligands CD80
and CD86. While an im-munoglobulin fusion protein construct of CTLA4 sup-pressed …
based im-munosuppressive regimens. Unfortunately, current immunotherapy targets
molecules with ubiquitous ex-pression resulting in devastating non-immune side effects. T-
cell costimulation has been identified as a new potential immunosuppressive target. The
best characterized pathway includes CD28, its homologue CTLA4 and their ligands CD80
and CD86. While an im-munoglobulin fusion protein construct of CTLA4 sup-pressed …